Published on 02/12/2025

Intended Use Storyboards for Inspections

Introduction to AI/ML Model Validation

The utilization of Artificial Intelligence (AI) and Machine Learning (ML) in GxP (Good Practice) analytics has become a cornerstone of modern pharmaceutical development. As the complexity of these technologies increases, regulatory bodies such as the FDA, EMA, and MHRA have provided guidance to ensure compliance with expected standards. The validation of AI/ML models is particularly crucial in the context of their intended use and data readiness, which form the foundation for the AI system’s reliability.

This article aims to provide a comprehensive step-by-step guide on creating Intended Use Storyboards specifically tailored for inspections. These storyboards serve as a visual representation of the intended use of AI/ML systems, addressing risk management, data preparedness, bias and fairness testing, model verification and validation, as well as compliance with critical regulations like 21 CFR Part 11 and GAMP 5.

Understanding Intended Use and Data Readiness

The concept of ‘intended use’ encapsulates the purpose for which an AI/ML model is designed, and it is vital to align this with data readiness during the validation process. AI/ML model validation is contingent on ensuring that the model functions correctly within its defined parameters and meets regulatory requirements. The first step is to assess the intended use which involves:

• Defining Model Objectives: Clearly document what the model is intended to do. This includes understanding the specific health outcomes it aims to support or predict.
• Identifying User Needs: Engage all stakeholders, including clinicians and data scientists, to define the model’s requirements and functional expectations.
• Regulatory Considerations: Familiarize yourself with guidelines from regulatory bodies, including necessary compliance measures.

Once the intended use has been established, data readinesscuration becomes critical. Data readiness ensures that the data used for training and feeding into the model meets quality standards. The steps to achieve this include:

• Data Collection: Implement methods to gather high-quality, relevant datasets that accurately represent the target population.
• Data Cleaning: Identify and eliminate inaccuracies and inconsistencies through robust cleaning processes.
• Data Preprocessing: Standardize and normalize data to prepare it for analysis.

Once the data is curated and the intended use defined, organizations can proceed to create the storyboard that details how these elements interact.

Creating Intended Use Storyboards

Intended Use Storyboards serve as a communication tool conveying how an AI/ML model operates within its intended context. To create effective storyboards, follow these steps:

Step 1: Define Key Components

Start the storyboard by clearly defining key components that illustrate the interconnectedness of intended use and data behavior within the model. Components typically include:

• AI/ML Model Specifications: Describe the technical aspects, including algorithms used, model structure, and performance metrics.
• Data Inputs: Visualize the datasets that feed into the model. Include data sources, formats, and data quality factors.
• Key Performance Indicators (KPIs): List KPIs that align with the model’s performance and intended outcomes, such as accuracy, precision, and recall.

Step 2: Visual Representation

Use flowcharts or diagrams to represent the workflow from data collection through processing to the final output. Clearly distinguish between the role of AI and human oversight in the decision-making process. For instance:

• Create a diagram showcasing how the raw data evolves into model predictions.
• Highlight feedback loops for human validation and intervention, illustrating a collaborative approach between AI and clinical professionals.

Step 3: Risk Assessment and Mitigation

Incorporate sections addressing intended use risks and mitigation strategies. Expected risks pertain to bias, product misinterpretation, or technical failures. Documentation should include:

• Bias and Fairness Testing: Evaluate the model for demographic bias and strategies employed to ensure fairness across clinical cohorts.
• Explainability (XAI): Discuss measures taken to enhance model interpretability for users and regulators, including techniques used to elucidate model behavior.
• Drift Monitoring & Re-validation: State how the model will be reviewed over time to monitor performance drift, ensuring it remains valid as data evolves.

Documentation and Audit Trails

With regulations such as 21 CFR Part 11 and Annex 11 requiring robust documentation standards, it is essential to maintain comprehensive records throughout the AI/ML model lifecycle. Ideal documentation practices should include:

• Data Management Records: Document every data interaction including collection methods, pre-processing steps, and any alterations made to the dataset.
• Model Development Logs: Maintain logs detailing the model training process, algorithm adjustments, validation and verification tests performed, and any experimentation notes.
• Approval Workflows: Establish traceable paths for stakeholder reviews and approvals, ensuring proper governance protocols are in place.

Audit trails should record changes to the model and its underlying data, providing accountability and traceability necessary for regulatory scrutiny.

AI Governance & Security Considerations

Implementing AI governance frameworks is paramount for ensuring compliance and model integrity. Considerations should encompass the following aspects:

• Data Privacy and Protection: Ensure adherence to GDPR and HIPAA regulations to protect sensitive patient information within datasets. Employ data anonymization and encryption as necessary.
• Access Control: Employ strict access mechanisms, detailing who can view or modify datasets and model outputs.
• Continuous Monitoring: Regularly assess models for vulnerabilities and rebalance against evolving regulatory requirements and ethical standards.

The convergence of data governance principles with AI technologies requires an ongoing commitment to security and robust performance verification standards.

Conclusion

In conclusion, Developing Intended Use Storyboards for AI/ML model validation in a regulated environment requires a comprehensive approach that addresses both intended use risk and data readiness. Adopting these structured processes not only aligns with regulatory expectations from bodies like the FDA, EMA, and MHRA, but it also solidifies confidence in the integrity and transparency of AI/ML systems used in healthcare. By following the outlined steps, pharmaceutical professionals can enhance their AI/ML initiatives and effectively navigate the complexities of validation, ensuring that innovations serve their intended clinical purposes while meeting stringent compliance requirements.